Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
- PMID: 38752578
- DOI: 10.1111/imr.13345
Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?
Abstract
Type 1 diabetes (T1D) is a chronic autoimmune disease targeting insulin-producing pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and environmental factors. In recent years, the advances in high-throughput sequencing have allowed researchers to elucidate the changes in the gut microbiota taxonomy and functional capacity that accompany T1D development. An increasing number of studies have shown a role of the gut microbiota in mediating immune responses in health and disease, including autoimmunity. Fecal microbiota transplantations (FMT) have been largely used in murine models to prove a causal role of the gut microbiome in disease progression and have been shown to be a safe and effective treatment in inflammatory human diseases. In this review, we summarize and discuss recent research regarding the gut microbiota-host interactions in T1D, the current advancement in therapies for T1D, and the usefulness of FMT studies to explore microbiota-host immunity encounters in murine models and to shape the course of human type 1 diabetes.
Keywords: fecal microbiota transplantation; microbiota; type 1 diabetes.
© 2024 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
References
REFERENCES
-
- Gregory GA, Robinson TIG, Linklater SE, et al. Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study. Lancet Diabetes Endocrinol. 2022;10(10):741‐760. doi:10.1016/S2213-8587(22)00218-2
-
- Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107842. doi:10.1016/j.diabres.2019.107842
-
- Gillespie KM, Bain SC, Barnett AH, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high‐risk HLA haplotypes. Lancet. 2004;364(9446):1699‐1700. doi:10.1016/s0140-6736(04)17357-1
-
- Hermann R, Knip M, Veijola R, et al. Temporal changes in the frequencies of HLA genotypes in patients with Type 1 diabetes–indication of an increased environmental pressure? Diabetologia. 2003;46(3):420‐425. doi:10.1007/s00125-003-1045-4
-
- Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet. 2009;373(9680):2027‐2033. doi:10.1016/s0140-6736(09)60568-7
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical